Search Results - "Chu, Hui–May"

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease by Prins, Niels D, Harrison, John E, Chu, Hui-May, Blackburn, Kelly, Alam, John J, Scheltens, Philip, Rowell, Zarate, Norden, Van

“…Abstract Background In preclinical studies, p38⍺ kinase is implicated in Alzheimer’s disease (AD) pathogenesis. In animal models, it mediates impaired synaptic…”
Get full text

Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir by Sarrazin, Christoph, Kieffer, Tara L, Bartels, Doug, Hanzelka, Brian, Müh, Ute, Welker, Martin, Wincheringer, Dennis, Zhou, Yi, Chu, Hui–May, Lin, Chao, Weegink, Christine, Reesink, Henk, Zeuzem, Stefan, Kwong, Ann D

“…Background & Aims: Telaprevir (VX-950), a hepatitis C virus (HCV) NS3·4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies…”
Get full text

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration by Jiang, Ying, Alam, John J., Gomperts, Stephen N., Maruff, Paul, Lemstra, Afina W., Germann, Ursula A., Stavrides, Philip H., Darji, Sandipkumar, Malampati, Sandeep, Peddy, James, Bleiwas, Cynthia, Pawlik, Monika, Pensalfini, Anna, Yang, Dun-Sheng, Subbanna, Shivakumar, Basavarajappa, Balapal S., Smiley, John F., Gardner, Amanda, Blackburn, Kelly, Chu, Hui-May, Prins, Niels D., Teunissen, Charlotte E., Harrison, John E., Scheltens, Philip, Nixon, Ralph A.

“…The endosome-associated GTPase Rab5 is a central player in the molecular mechanisms leading to degeneration of basal forebrain cholinergic neurons (BFCN), a…”
Get full text

Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C by Forestier, Nicole, Reesink, Hendrik W., Weegink, Christine J., McNair, Lindsay, Kieffer, Tara L., Chu, Hui‐May, Purdy, Susan, Jansen, Peter L.M., Zeuzem, Stefan

“…Telaprevir (VX‐950), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, substantially decreased plasma HCV RNA levels in a prior clinical study. The…”
Get full text

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease by Scheltens, Philip, Prins, Niels, Lammertsma, Adriaan, Yaqub, Maqsood, Gouw, Alida, Wink, Alle Meije, Chu, Hui‐May, Berckel, Bart N. M., Alam, John

“…Objective The aim of this study was to preliminarily evaluate an oral small molecule p38α kinase inhibitor in patients with early Alzheimer's disease (AD) for…”
Get full text

Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions by Tolbert, Dwain, Bekersky, Ihor, Chu, Hui-May, Ette, Ene I.

“…A metabolic mechanism‐based characterization of antiepileptic drug‐drug interactions (DDIs) with clobazam in patients with Lennox‐Gastaut syndrome (LGS) was…”
Get full text

An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics by Tolbert, Dwain, Bekersky, Ihor, Chu, Hui-May, Ette, Ene I.

“…An integrative population pharmacokinetics (PPK)–based approach was used to characterize the effect of hepatic impairment on clobazam PK and its major…”
Get full text

Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning by Manak, Michael S., Varsanik, Jonathan S., Hogan, Brad J., Whitfield, Matt J., Su, Wendell R., Joshi, Nikhil, Steinke, Nicolai, Min, Andrew, Berger, Delaney, Saphirstein, Robert J., Dixit, Gauri, Meyyappan, Thiagarajan, Chu, Hui-May, Knopf, Kevin B., Albala, David M., Sant, Grannum R., Chander, Ashok C.

“…The risk stratification of prostate cancer and breast cancer tumours from patients relies on histopathology, selective genomic testing, or on other methods…”
Get full text

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies by Alam, John J., Maruff, Paul, Doctrow, Susan R., Chu, Hui-May, Conway, Jennifer, Gomperts, Stephen N., Teunissen, Charlotte

“…BACKGROUND AND OBJECTIVESIn a proportion of patients, dementia with Lewy bodies (DLB) is associated with Alzheimer disease (AD) copathology, which is linked to…”
Get full text

Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome by Tolbert, Dwain, Chu, Hui-May, Ette, Ene I.

“…•An efficacious pediatric clobazam (CLB) dosing regimen identified by PopPK modeling.•Evaluation/validation showed the model adequately described CLB and N-CLB…”
Get full text

EVIDENCE THAT ORAL P38 MAPK ALPHA ANTAGONISM IMPROVES EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE (AD) by Prins, Niels D., Alam, John, Chu, Hui-May, Scheltens, Philip

Get full text

Data supplementation: a pharmacokinetic/pharmacodynamic knowledge creation approach for characterizing an unexplored region of the response surface by Ette, Ene I, Chu, Hui-May, Godfrey, Christopher J

“…To develop a data supplementation [i.e., a pharmacokinetic/pharmacodynamics (PK/PD) knowledge creation] approach for generating supplemental data to be used in…”
Get full text

Pharmacometrics of Clobazam in Pediatrics: Population PK Modeling to Predict Effective Clobazam Doses for Dravet Syndrome (P4.265) by Tolbert, Dwain, Chu, Hui-May, Ette, Ene

“…Abstract only…”
Get full text

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease by Zhou, Yi, Bartels, Doug J, Hanzelka, Brian L, Müh, Ute, Wei, Yunyi, Chu, Hui-May, Tigges, Ann M, Brennan, Debra L, Rao, B Govinda, Swenson, Lora, Kwong, Ann D, Lin, Chao

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

P2‐011: PHARMACOKINETIC‐PHARMACODYNAMIC MODELING OF THE THERAPEUTIC EFFECT OF ORAL P38 MAPK ALPHA ANTAGONISM ON EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE (AD) by Chu, Hui-May, Prins, Niels D., Ette, Ene, Alam, John

Get full text

The PK/PD Basis for Clobazam Use in Refractory Seizures: Is There a Need for Clobazam Dosage Reduction in the Presence of Other Antiepileptic Drugs (AEDs)? (P4.266) by Tolbert, Dwain, Klein, Pavel, Gidal, Barry, Chu, Hui-May, Ette, Ene

“…Abstract only…”
Get full text

Clobazam Drug-Drug Interactions: A Mechanism-Based Characterization Using a Model-Based Approach (P4.259) by Tolbert, Dwain, Bekersky, Ihor, Chu, Hui-May, Ette, Ene

“…Abstract only…”
Get full text

Effects of Hepatic Impairment on Clobazam Pharmacokinetics: An Integrative, Model-Based Approach (P1.259) by Ette, Ene, Bekersky, Ihor, Chu, Hui-May, Tolbert, Dwain

“…Abstract only…”
Get full text

PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THE THERAPEUTIC EFFECT OF ORAL P38 MAPK ALPHA ANTAGONISM ON EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE (AD) by Chu, Hui-May, Prins, Niels D., Ette, Ene, Alam, John

Get full text

[O2–09–06]: EVIDENCE THAT ORAL P38 MAPK ALPHA ANTAGONISM IMPROVES EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER's DISEASE (AD) by Prins, Niels D., Alam, John, Chu, Hui‐May, Scheltens, Philip

Get full text